<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205581</url>
  </required_header>
  <id_info>
    <org_study_id>FLUHD</org_study_id>
    <nct_id>NCT01205581</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV</brief_title>
  <official_title>Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated
      influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV. Subjects with cancer or
      HIV will be vaccinated twice with one of the two vaccines and evaluated for development of
      immune responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are to compare the immune response of Fluzone HD, a
      high-dose, trivalent influenza vaccine (TIV), to Fluzone, a standard-dose TIV, in children
      with cancer and in children with HIV.

      The secondary objectives of this study are to:

        -  Describe the safety and reactogenicity of high-dose and standard-dose TIV.

        -  Compare the immunogenicity induced by 1 dose, compared to 2 doses, of high-dose and
           standard-dose TIV.

        -  Describe the relationship between baseline lymphocyte numbers/function and
           robustness/durability of the immune response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Seroconversion After 1 Dose of Vaccine</measure>
    <time_frame>at least 21 days after first dose, which is given at the time of baseline evaluation visit, and prior to second dose</time_frame>
    <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Seroprotection After 1 Dose of Vaccine</measure>
    <time_frame>at least 21 days after first dose, which is given at the time of baseline evaluation visit, and prior to second dose</time_frame>
    <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Seroprotection After Second Dose of Vaccine</measure>
    <time_frame>21 to 42 days after second dose</time_frame>
    <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Grade 3 and Grade 4 Adverse Events Possibly, Probably, or Definitely Attributable to Fluzone or Fluzone HD</measure>
    <time_frame>From initial vaccine administration through up to 8 months</time_frame>
    <description>Number of participants reporting grade 3 and grade 4 adverse events possibly, probably, or definitely attributable to Fluzone or Fluzone HD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone HD</measure>
    <time_frame>at least 21 days after each dose of vaccine</time_frame>
    <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone HD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone SD</measure>
    <time_frame>at least 21 days after each dose of vaccine</time_frame>
    <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone SD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Vaccine Response by Seroconversion Compared by Absolute Lymphocyte Count (ALC)</measure>
    <time_frame>ALC at baseline and vaccine response at least 21 days after last dose of vaccine</time_frame>
    <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Vaccine Response by Seroprotection Compared by Absolute Lymphocyte Count (ALC)</measure>
    <time_frame>ALC at baseline and vaccine response at least 21 days after last dose of vaccine</time_frame>
    <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Local Reactogenicity Events After First Dose</measure>
    <time_frame>First 14 days after vaccination</time_frame>
    <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Local Reactogenicity Events After Second Dose</measure>
    <time_frame>First 14 days after vaccination</time_frame>
    <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Systemic Reactogenicity Events After First Dose</measure>
    <time_frame>First 14 days after vaccination</time_frame>
    <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Systemic Reactogenicity Events After Second Dose</measure>
    <time_frame>First 14 days after vaccination</time_frame>
    <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Geometric Mean Titer (GMT) by HAI</measure>
    <time_frame>Pre-vaccination, post-vaccination and 9 months after vaccination</time_frame>
    <description>Serum antibody levels expressed as the reciprocal of the dilution needed to inhibit hemagglutination in vitro.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Geometric Mean Ratios (GMR) by HAI</measure>
    <time_frame>Pre-vaccination, post-vaccination and 9 months after vaccination</time_frame>
    <description>GMTs compared to each other as a ratio of the pre- and post-vaccine titers and as the ratio post-last dose to 9 months later.
GMRs were compared pre- to post-vaccination and post- vaccination to 9 months later.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>HIV</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Leukemia-HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukemia-SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid Tumor-HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid Tumor-SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-HD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-SD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone High Dose Vaccine</intervention_name>
    <description>Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.</description>
    <arm_group_label>Leukemia-HD</arm_group_label>
    <arm_group_label>Solid Tumor-HD</arm_group_label>
    <arm_group_label>HIV-HD</arm_group_label>
    <other_name>Fluzone-HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Standard Dose Vaccine</intervention_name>
    <description>Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.</description>
    <arm_group_label>Leukemia-SD</arm_group_label>
    <arm_group_label>Solid Tumor-SD</arm_group_label>
    <arm_group_label>HIV-SD</arm_group_label>
    <other_name>Fluzone-SD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 3 years (on or past their 3rd birthday) through 21 years of age (not yet reached
             their 22nd birthday) at the time of entry into the study.

          -  Written informed consent (and assent, if applicable) obtained.

          -  Participant has a diagnosis of cancer or HIV.

          -  If subject has cancer, currently receiving chemotherapy and /or radiotherapy for the
             treatment of cancer or has received chemotherapy in the past 12 weeks

        Exclusion Criteria

          -  Severe hypersensitivity to egg proteins or any component of Fluzone, or
             life-threatening reactions after any previous administration of any influenza vaccine;

          -  History of Guillain-Barre´ syndrome in the subject or subject's family (parents,
             siblings, half siblings, or children);

          -  Not willing to agree to acceptable birth control for three months after study
             immunization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan A McCullers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <results_first_submitted>July 24, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluzone</keyword>
  <keyword>Trivalent Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were ≥3-21 yrs. at study entry with diagnosis of cancer or HIV. Those with cancer were receiving chemotherapy and/or radiotherapy or had received chemotherapy in the prior 12 weeks. One participant was enrolled but was lost to follow up prior to randomization. 84 participants were randomized between 9/2010 and 10/2011.</recruitment_details>
      <pre_assignment_details>Participants excluded if they had: pre-vaccination titer of ≥1:2560, severe hypersensitivity to egg proteins or any component of Fluzone, life-threatening reaction after prior influenza vaccine, history of Guillain-Barre syndrome in subject/subject's family, or unwilling to agree to acceptable birth control for 3 months after each dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Leukemia-HD</title>
          <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="P2">
          <title>Leukemia-SD</title>
          <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
        </group>
        <group group_id="P3">
          <title>Solid Tumor-HD</title>
          <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="P4">
          <title>Solid Tumor-SD</title>
          <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
        </group>
        <group group_id="P5">
          <title>HIV-HD</title>
          <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="P6">
          <title>HIV-SD</title>
          <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This was an open-label study where participants were randomized at a 1:1 ratio into Fluzone high-dose (HD) and Fluzone standard dose (SD) groups by disease group with the use of a computer-generated randomization schedule.</population>
      <group_list>
        <group group_id="B1">
          <title>Leukemia-HD</title>
          <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="B2">
          <title>Leukemia-SD</title>
          <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
        </group>
        <group group_id="B3">
          <title>Solid Tumor-HD</title>
          <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="B4">
          <title>Solid Tumor-SD</title>
          <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
        </group>
        <group group_id="B5">
          <title>HIV-HD</title>
          <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="B6">
          <title>HIV-SD</title>
          <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="5.7"/>
                    <measurement group_id="B2" value="11.8" spread="5.1"/>
                    <measurement group_id="B3" value="12.4" spread="4.2"/>
                    <measurement group_id="B4" value="11.7" spread="4.5"/>
                    <measurement group_id="B5" value="16.7" spread="5.6"/>
                    <measurement group_id="B6" value="19.9" spread="1.8"/>
                    <measurement group_id="B7" value="14.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Seroconversion After 1 Dose of Vaccine</title>
        <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
        <time_frame>at least 21 days after first dose, which is given at the time of baseline evaluation visit, and prior to second dose</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-HD</title>
            <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-SD</title>
            <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-HD</title>
            <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-SD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>HIV-HD</title>
            <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-SD</title>
            <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Seroconversion After 1 Dose of Vaccine</title>
          <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Grade 3 and Grade 4 Adverse Events Possibly, Probably, or Definitely Attributable to Fluzone or Fluzone HD</title>
        <description>Number of participants reporting grade 3 and grade 4 adverse events possibly, probably, or definitely attributable to Fluzone or Fluzone HD.</description>
        <time_frame>From initial vaccine administration through up to 8 months</time_frame>
        <population>Adverse events of Fluzone HD and Fluzone are provided as combined data from cancer and HIV patients, since there is no reason to believe one group is more susceptible to adverse events than the other.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose FluzoneHD</title>
            <description>41 participants received 80 doses of high-dose FluzoneHD.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Fluzone</title>
            <description>42 participants received 82 doses of standard-dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Grade 3 and Grade 4 Adverse Events Possibly, Probably, or Definitely Attributable to Fluzone or Fluzone HD</title>
          <description>Number of participants reporting grade 3 and grade 4 adverse events possibly, probably, or definitely attributable to Fluzone or Fluzone HD.</description>
          <population>Adverse events of Fluzone HD and Fluzone are provided as combined data from cancer and HIV patients, since there is no reason to believe one group is more susceptible to adverse events than the other.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone HD</title>
        <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone HD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
        <time_frame>at least 21 days after each dose of vaccine</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-1 Dose</title>
            <description>Patients with a diagnosis of leukemia who received one dose of high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-2 Doses</title>
            <description>Patients with a diagnosis of leukemia who received 2 doses of high dose Fluzone HD.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-1 Dose</title>
            <description>Patients with a diagnosis of solid tumor who received one dose of high dose Fluzone HD.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-2 Doses</title>
            <description>Patients with a diagnosis of solid tumor who received 2 doses of high dose Fluzone HD.</description>
          </group>
          <group group_id="O5">
            <title>HIV-1 Dose</title>
            <description>Patients with a diagnosis of HIV who received one dose of high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-2 Doses</title>
            <description>Patients with a diagnosis of HIV who received 2 doses of high dose Fluzone HD.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone HD</title>
          <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone HD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="72"/>
                    <measurement group_id="O6" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone SD</title>
        <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone SD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
        <time_frame>at least 21 days after each dose of vaccine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-1 Dose</title>
            <description>Patients with a diagnosis of leukemia who received one dose of high dose Fluzone SD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-2 Doses</title>
            <description>Patients with a diagnosis of leukemia who received 2 doses of high dose Fluzone SD.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-1 Dose</title>
            <description>Patients with a diagnosis of solid tumor who received one dose of high dose Fluzone SD.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-2 Doses</title>
            <description>Patients with a diagnosis of solid tumor who received 2 doses of high dose Fluzone SD.</description>
          </group>
          <group group_id="O5">
            <title>HIV-1 Dose</title>
            <description>Patients with a diagnosis of HIV who received one dose of high dose Fluzone SD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-2 Doses</title>
            <description>Patients with a diagnosis of HIV who received 2 doses of high dose Fluzone SD.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Sero-conversion for 1 Dose vs. 2 Doses of Fluzone SD</title>
          <description>The rate of seroconversion to the 3 antigens contained in the vaccine was determined by hemagglutination-inhibition test and was compared by disease.
The immune response of 1 dose vs. 2 doses of Fluzone SD was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroconversion was defined as a post-vaccine HAI titer ≥40 if baseline was &lt;10, or a 4-fold rise in HAI titer if the baseline ≥10.</description>
          <units>percentrage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="65"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Vaccine Response by Seroconversion Compared by Absolute Lymphocyte Count (ALC)</title>
        <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
        <time_frame>ALC at baseline and vaccine response at least 21 days after last dose of vaccine</time_frame>
        <population>30 participants did not have ALC data collected at baseline evaluation because they had complete blood count (CBC) ordered without differential count.</population>
        <group_list>
          <group group_id="O1">
            <title>ALC &lt;1000 Cells/mm³</title>
            <description>Participants whose ALC was &lt;1000 cells/mm³ were analyzed.</description>
          </group>
          <group group_id="O2">
            <title>ALC ≥1000 Cells/mm³</title>
            <description>Participants whose ALC was ≥1000 cells/mm³ were analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Vaccine Response by Seroconversion Compared by Absolute Lymphocyte Count (ALC)</title>
          <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
          <population>30 participants did not have ALC data collected at baseline evaluation because they had complete blood count (CBC) ordered without differential count.</population>
          <units>percentagae of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Seroprotection After 1 Dose of Vaccine</title>
        <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
        <time_frame>at least 21 days after first dose, which is given at the time of baseline evaluation visit, and prior to second dose</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-HD</title>
            <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-SD</title>
            <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-HD</title>
            <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-SD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>HIV-HD</title>
            <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-SD</title>
            <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Seroprotection After 1 Dose of Vaccine</title>
          <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Seroprotection After Second Dose of Vaccine</title>
        <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
        <time_frame>21 to 42 days after second dose</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-HD</title>
            <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-SD</title>
            <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-HD</title>
            <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-SD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>HIV-HD</title>
            <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-SD</title>
            <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Seroprotection After Second Dose of Vaccine</title>
          <description>The immune response of Fluzone HD to Fluzone was determined using the hemagglutination-inhibition (HAI) assay to each of the 3 antigens contained in the vaccine: H1, H3 and B. Seroprotection was defined as a post-vaccine HAI titer ≥40.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B antigen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Vaccine Response by Seroprotection Compared by Absolute Lymphocyte Count (ALC)</title>
        <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
        <time_frame>ALC at baseline and vaccine response at least 21 days after last dose of vaccine</time_frame>
        <population>30 participants did not have ALC data collected at baseline evaluation because they had complete blood count (CBC) ordered without differential count.</population>
        <group_list>
          <group group_id="O1">
            <title>ALC &lt;1000 Cells/mm³</title>
            <description>Participants whose ALC was &lt;1000 cells/mm³ were analyzed.</description>
          </group>
          <group group_id="O2">
            <title>ALC ≥1000 Cells/mm³</title>
            <description>Participants whose ALC was ≥1000 cells/mm³ were analyzed.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Vaccine Response by Seroprotection Compared by Absolute Lymphocyte Count (ALC)</title>
          <description>The relationship between baseline lymphocyte numbers/function and robustness of the immune response will be described through descriptive analysis of relationships between pre-defined variables.</description>
          <population>30 participants did not have ALC data collected at baseline evaluation because they had complete blood count (CBC) ordered without differential count.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Local Reactogenicity Events After First Dose</title>
        <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
        <time_frame>First 14 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose FluzoneHD</title>
            <description>41 participants received 80 doses of high-dose FluzoneHD.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Fluzone</title>
            <description>42 participants received 82 doses of standard-dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Local Reactogenicity Events After First Dose</title>
          <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Local Reactogenicity Events After Second Dose</title>
        <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
        <time_frame>First 14 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose FluzoneHD</title>
            <description>41 participants received 80 doses of high-dose FluzoneHD.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Fluzone</title>
            <description>42 participants received 82 doses of standard-dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Local Reactogenicity Events After Second Dose</title>
          <description>Number of moderate or greater local reactogenicity events associated with the administration of Fluzone or FluzoneHD. Local reactions were defined as pain, redness, or induration.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Systemic Reactogenicity Events After First Dose</title>
        <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
        <time_frame>First 14 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose FluzoneHD</title>
            <description>41 participants received 80 doses of high-dose FluzoneHD.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Fluzone</title>
            <description>42 participants received 82 doses of standard-dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Systemic Reactogenicity Events After First Dose</title>
          <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Systemic Reactogenicity Events After Second Dose</title>
        <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
        <time_frame>First 14 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-dose FluzoneHD</title>
            <description>41 participants received 80 doses of high-dose FluzoneHD.</description>
          </group>
          <group group_id="O2">
            <title>Standard Dose Fluzone</title>
            <description>42 participants received 82 doses of standard-dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Systemic Reactogenicity Events After Second Dose</title>
          <description>Number of moderate or greater systemic reactogenicity event associated with the administration of Fluzone or FluzoneHD. Systemic reactions were defined as muscle ache, fatigue, or fever.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Geometric Mean Titer (GMT) by HAI</title>
        <description>Serum antibody levels expressed as the reciprocal of the dilution needed to inhibit hemagglutination in vitro.</description>
        <time_frame>Pre-vaccination, post-vaccination and 9 months after vaccination</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-HD</title>
            <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-SD</title>
            <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-HD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-SD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>HIV-HD</title>
            <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-SD</title>
            <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Geometric Mean Titer (GMT) by HAI</title>
          <description>Serum antibody levels expressed as the reciprocal of the dilution needed to inhibit hemagglutination in vitro.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 Antigen/Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="17" upper_limit="49"/>
                    <measurement group_id="O2" value="50" lower_limit="22" upper_limit="111"/>
                    <measurement group_id="O3" value="57" lower_limit="16" upper_limit="203"/>
                    <measurement group_id="O4" value="40" lower_limit="20" upper_limit="81"/>
                    <measurement group_id="O5" value="71" lower_limit="37" upper_limit="137"/>
                    <measurement group_id="O6" value="67" lower_limit="40" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1 Antigen/Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="62" upper_limit="221"/>
                    <measurement group_id="O2" value="161" lower_limit="82" upper_limit="317"/>
                    <measurement group_id="O3" value="580" lower_limit="157" upper_limit="2137"/>
                    <measurement group_id="O4" value="148" lower_limit="84" upper_limit="260"/>
                    <measurement group_id="O5" value="373" lower_limit="264" upper_limit="528"/>
                    <measurement group_id="O6" value="267" lower_limit="188" upper_limit="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1 Antigen/9 Months Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="11" upper_limit="87"/>
                    <measurement group_id="O2" value="85" lower_limit="14" upper_limit="533"/>
                    <measurement group_id="O3" value="403" lower_limit="33" upper_limit="4940"/>
                    <measurement group_id="O4" value="80" lower_limit="12" upper_limit="533"/>
                    <measurement group_id="O5" value="279" lower_limit="145" upper_limit="535"/>
                    <measurement group_id="O6" value="174" lower_limit="93" upper_limit="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Antigen/Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="12" upper_limit="58"/>
                    <measurement group_id="O2" value="25" lower_limit="10" upper_limit="61"/>
                    <measurement group_id="O3" value="20" lower_limit="6" upper_limit="69"/>
                    <measurement group_id="O4" value="22" lower_limit="9" upper_limit="53"/>
                    <measurement group_id="O5" value="42" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="O6" value="49" lower_limit="31" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Antigen/Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" lower_limit="49" upper_limit="394"/>
                    <measurement group_id="O2" value="63" lower_limit="21" upper_limit="188"/>
                    <measurement group_id="O3" value="215" lower_limit="104" upper_limit="445"/>
                    <measurement group_id="O4" value="109" lower_limit="31" upper_limit="381"/>
                    <measurement group_id="O5" value="154" lower_limit="105" upper_limit="226"/>
                    <measurement group_id="O6" value="143" lower_limit="97" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Antigen/9 Months Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="16" upper_limit="148"/>
                    <measurement group_id="O2" value="40" lower_limit="13" upper_limit="123"/>
                    <measurement group_id="O3" value="101" lower_limit="28" upper_limit="360"/>
                    <measurement group_id="O4" value="143" lower_limit="49" upper_limit="416"/>
                    <measurement group_id="O5" value="70" lower_limit="44" upper_limit="111"/>
                    <measurement group_id="O6" value="102" lower_limit="52" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Antigen/Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8" upper_limit="31"/>
                    <measurement group_id="O2" value="29" lower_limit="15" upper_limit="57"/>
                    <measurement group_id="O3" value="17" lower_limit="8" upper_limit="35"/>
                    <measurement group_id="O4" value="23" lower_limit="12" upper_limit="47"/>
                    <measurement group_id="O5" value="33" lower_limit="23" upper_limit="48"/>
                    <measurement group_id="O6" value="34" lower_limit="23" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Antigen/Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181" lower_limit="89" upper_limit="371"/>
                    <measurement group_id="O2" value="113" lower_limit="36" upper_limit="357"/>
                    <measurement group_id="O3" value="195" lower_limit="33" upper_limit="1138"/>
                    <measurement group_id="O4" value="202" lower_limit="83" upper_limit="488"/>
                    <measurement group_id="O5" value="160" lower_limit="108" upper_limit="237"/>
                    <measurement group_id="O6" value="172" lower_limit="100" upper_limit="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Antigen/9 Months Post-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="13"/>
                    <measurement group_id="O2" value="13" lower_limit="6" upper_limit="28"/>
                    <measurement group_id="O3" value="16" lower_limit="6" upper_limit="43"/>
                    <measurement group_id="O4" value="11" lower_limit="5" upper_limit="23"/>
                    <measurement group_id="O5" value="13" lower_limit="9" upper_limit="19"/>
                    <measurement group_id="O6" value="13" lower_limit="9" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Geometric Mean Ratios (GMR) by HAI</title>
        <description>GMTs compared to each other as a ratio of the pre- and post-vaccine titers and as the ratio post-last dose to 9 months later.
GMRs were compared pre- to post-vaccination and post- vaccination to 9 months later.</description>
        <time_frame>Pre-vaccination, post-vaccination and 9 months after vaccination</time_frame>
        <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
        <group_list>
          <group group_id="O1">
            <title>Leukemia-HD</title>
            <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O2">
            <title>Leukemia-SD</title>
            <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumor-HD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumor-SD</title>
            <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
          </group>
          <group group_id="O5">
            <title>HIV-HD</title>
            <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
          </group>
          <group group_id="O6">
            <title>HIV-SD</title>
            <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Geometric Mean Ratios (GMR) by HAI</title>
          <description>GMTs compared to each other as a ratio of the pre- and post-vaccine titers and as the ratio post-last dose to 9 months later.
GMRs were compared pre- to post-vaccination and post- vaccination to 9 months later.</description>
          <population>Two patients in the HIV-HD group were excluded because data was only available at baseline. These 2 patients were lost for follow-up before evaluation for post-vaccine immune response.</population>
          <units>Ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1 post- over pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="3.7"/>
                    <measurement group_id="O5" value="5.2"/>
                    <measurement group_id="O6" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1 post-vaccination over 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="1.3"/>
                    <measurement group_id="O6" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 post- over pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="3.7"/>
                    <measurement group_id="O6" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 post-vaccination over 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="0.8"/>
                    <measurement group_id="O5" value="2.2"/>
                    <measurement group_id="O6" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B post- over pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="8.6"/>
                    <measurement group_id="O5" value="4.8"/>
                    <measurement group_id="O6" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B post-vaccination over 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="12.3"/>
                    <measurement group_id="O4" value="18.0"/>
                    <measurement group_id="O5" value="12.1"/>
                    <measurement group_id="O6" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for 21 days after each dose of vaccine. No &quot;other&quot; adverse events were observed.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leukemia-HD</title>
          <description>Patients with a diagnosis of leukemia who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="E2">
          <title>Leukemia-SD</title>
          <description>Patients with a diagnosis of leukemia who received the standard dose Fluzone.</description>
        </group>
        <group group_id="E3">
          <title>Solid Tumor-HD</title>
          <description>Patients with a diagnosis of solid tumor who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="E4">
          <title>Solid Tumor-SD</title>
          <description>Patients with a diagnosis of solid tumor who received the standard dose Fluzone.</description>
        </group>
        <group group_id="E5">
          <title>HIV-HD</title>
          <description>Patients with a diagnosis of HIV who received the high dose Fluzone HD.</description>
        </group>
        <group group_id="E6">
          <title>HIV-SD</title>
          <description>Patients with a diagnosis of HIV who received the standard dose Fluzone.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.02)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>In 9-year-old with history of neurologic disorder who received FluzoneHD after recovery from sedation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon McCullers, MD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>info@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

